# US 2024/0200049 A1 · Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200049 A1
- Document ID: US20240200049A1
- Status: Published application
- Kind: A1
- Application number: 18/194,176
- Filed: 2023-03-31
- Published: 2024-06-20
- Earliest claimed: 2014-02-06
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Farren Isaacs; Miriam Amiram; Adrian Haimovich; Dieter Soll
- Web page: https://patentgrep.com/patent/US20240200049A1

## CPC

- C12N 9/93: {Ligases (6)}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12Y 601/01: Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Compositions, systems, and methods for preparation of polypeptides having multiple iterations of non-standard amino acids are provided. The compositions and method can be used to produce recombinant proteins at a greater yield than the same or similar polypeptides made using conventional compositions, systems, and methods. Accordingly, in some embodiments, the polypeptides are ones that could not be made using conventional methods and reagents, or could not be made a sufficient yield or purity to serve a practical purpose using conventional methods and reagents. Polypeptides made using the disclosed compositions, systems, and methods are also provided.

## Claims

### Claim at position 1

-14. (canceled)

### Claim 15

An isolated variant AARS comprising the non-standard amino acid (amino acid ligand) binding pocket of any of SEQ ID NOS:2-15, the tRNA anticodon recognition interface of any of SEQ ID NO:2-15, or a combination thereof.

### Claim 16 (depends on 15)

The isolated variant AARS of claim 15 comprising the amino acid sequence of any of SEQ ID NOS:2-15.

### Claim 17 (depends on 15)

A method of making a polypeptide comprising one or more iterations of a non-standard amino acid comprising expressing a messenger RNA (mRNA) encoding the target protein in a system comprising:
orthogonal translation system (OTS) comprising the nucleic acid sequence encoding the variant AARS of claim 15 and its cognate tRNA operably linked to expression control sequences and transformed, transfected, or integrated into a genomically recoded organism (GRO) with at least one codon reduced or absent from its genome, and
a plurality of a non-standard amino acids,
wherein the mRNA comprises a nucleic acid sequence comprising at least one iteration of the codon deleted from the GRO,
and wherein the tRNA comprises and anticodon that can bind to the codon reduced or absent from the GRO.

### Claim 18 (depends on 17)

The method of claim 17 wherein the GRO is E. coli.

### Claim 19 (depends on 18)

The method of claim 18 wherein the codon reduced or absent from the GRO is TAG.

### Claim 20 (depends on 19)

The method of claim 19 wherein the non-standard amino acid is selected is pAcF, pAzF, StyA, 4IF, 4BrF, 4ClF, 4MeF, 4Cf3F, MeY, 4NO2F, 4BuF, BuY, 2NaA, PhF, or 3,4-dihydroxyphenylalanine.

### Claim 21 (depends on 17)

A polypeptide translated by the method of claim 17.

### Claim 22

A polypeptide comprising the amino acid sequence of any of SEQ ID NOS:20-27.

### Claim 23 (depends on 17)

A polypeptide comprising the amino acid sequence of any of SEQ ID NOS:19-27, wherein the polypeptide was made according to the method of claim 17.

### Claim 24 (depends on 21)

The polypeptide of claim 21 wherein “X” is pAcF, pAzF, Sty A, 4IF, 4BrF, 4ClF, 4MeF, 4Cf3F, MeY, 4NO2F, 4BuF, BuY, 2NaA, PhF, or 3,4-dihydroxyphenylalanine.

### Claim 25 (depends on 21)

The polypeptide of claim 21 comprising at least 20 iterations of a non-standard amino acid.

### Claim 26 (depends on 21)

A pharmaceutical compositing comprising the polypeptide of claim 21.

### Claim 27 (depends on 21)

A device coated with the polypeptide of claim 21.

### Claim 28 (depends on 15)

A host cell comprising the variant AARS of claim 15.

### Claim 29 (depends on 28)

The host cell of claim 28, wherein the variant AARS is integrated into the host cell's genome.

### Claim 30 (depends on 29)

The host cell of claim 29, wherein the host cell is a genomically recoded E. coli.

### Claim 31

A polypeptide comprising the amino acid sequence of any of SEQ ID NOS:19-27, wherein “X” is 3,4-dihydroxyphenylalanine or pAzF and the side chain of pAzF is conjugated to a molecule.

### Claim at position 19

-40. (canceled)

### Claim 41 (depends on 31)

The polypeptide of claim 31, wherein molecule is a fatty acid.

### Claim 42 (depends on 41)

The polypeptide of claim 41, wherein the fatty acid is fatty acids palmitic acid.

### Claim 43 (depends on 16)

The isolated variant AARS of claim 16 comprising the amino acid sequence of any of SEQ ID NO: 11 or 12.
